Skip to main content
Menu

Posts tagged with "Covid-19"

  • Clinical Trials

    Vaccine Data From Novavax

    Several days after making some headlines with a press release about the data, the Novavax vaccine effort has published on Medrxiv. The is the first look at human data we have at an approach using recombinant coronavirus proteins (plus an adjuvant, in this case a proprietary saponin natural product). The protein itself is produced in… Read More
  • Covid-19

    Regeneron’s Monoclonal Antibody Cocktail in Primates

    I’m very glad to see some data emerging on the monoclonal antibody therapies that have been in the works. Regeneron  and Eli Lilly/Abcellera are two of the front-runners in this field, which could pick up some very much needed slack while the many vaccine trials are going on. And late yesterday a preprint emerged from… Read More
  • Clinical Trials

    Coronavirus Challenges in Primates, Compared

    We have a sudden influx over the last few days of preclinical rhesus challenge studies with various coronavirus vaccines, and it’s only natural to try to compare them. I have worked up a table with all four of the current results and the previously reported SinoVac inactivated virus vaccine, whose rhesus challenge numbers were officially… Read More
  • Clinical Trials

    The Latest Repurposing News (Two Parter: IL-6 and Apilimod)

    As everyone knows, there have been a lot of attempts to repurpose existing therapies for the coronavirus pandemic. I’ve covered several of these along the way, but it’s time for some updates. The work that’s been going on not only adds to our knowledge about treatment for infected patients, but it should – ideally – Read More
  • Clinical Trials

    Pfizer and BioNTech Pick a Vaccine Candidate

    In a bit of a surprise move, Pfizer and their partner BioNTech announced yesterday that they were moving their BNT162b2 mRNA vaccine candidate forward into Phase II/III trials. The surprise was because all the publications from this effort so far had been on another one of their four candidates, BNT162b1. Fans keeping score at home will know… Read More
  • Business and Markets

    Formulating RNA – And Owning It

    Headlines appeared last night about Moderna losing a patent case that affects its coronavirus vaccine work. I know from long experience on this blog that any discussion of patent and IP issues has an effect on my readership traffic numbers that looks like I’m paying folks not to click on my links that day, but… Read More
  • Clinical Trials

    New Data on the CanSino Vaccine

    And now we have more data on the CanSino vaccine, another adenovirus vector (but this one using Ad5, a much more common one in the human population). Their initial Phase I data are discussed here. So what else do we know now? Well, that one was open label and non-randomized, whereas this one is fully controlled. Read More
  • Clinical Trials

    New Data on the Oxford/AZ Vaccine

    The hype began building late last week around the Oxford vaccine results released today, and I will confess to wondering just what was going on. The British press has a history of going berserk over drug research – I wouldn’t care to count how many times Alzheimer’s “breakthroughs” have hit the headlines over there, an… Read More
  • Clinical Trials

    More Pfizer Phase I Results: Antibodies, Viral Mutations, and T Cells

    Recent posts here have gone into Moderna’s Phase I vaccine data, Pfizer’s Phase I vaccine data, what we don’t know yet about the relationship between T-cells, antibodies, and immunity to the coronavirus, and some new data that are starting to fill in those gaps. This morning comes a new preprint from the Pfizer/BioNTech team that… Read More
  • Covid-19

    New Data on T Cells and the Coronavirus

    Well, I was writing just the other day about what we don’t know about the T-cell response to coronavirus infection, and as of today we know quite a bit more. And from what I can see, we have encouraging news, mixed with some things that we’re going to need to keep an eye on. Here’s… Read More
123...